- Home
- LMB vs GYRE Comparison
LMB vs GYRE Comparison
Compare LMB & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- GYRE
- Stock Information
- Founded
- LMB 1901
- GYRE 2002
- Country
- LMB United States
- GYRE United States
- Employees
- LMB N/A
- GYRE N/A
- Industry
- LMB Engineering & Construction
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- GYRE Health Care
- Exchange
- LMB Nasdaq
- GYRE Nasdaq
- Market Cap
- LMB 1.6B
- GYRE 897.1M
- IPO Year
- LMB 2014
- GYRE N/A
- Fundamental
- Price
- LMB $145.30
- GYRE $8.15
- Analyst Decision
- LMB Strong Buy
- GYRE
- Analyst Count
- LMB 3
- GYRE 0
- Target Price
- LMB $136.67
- GYRE N/A
- AVG Volume (30 Days)
- LMB 202.9K
- GYRE 207.6K
- Earning Date
- LMB 08-05-2025
- GYRE 08-12-2025
- Dividend Yield
- LMB N/A
- GYRE N/A
- EPS Growth
- LMB 31.50
- GYRE N/A
- EPS
- LMB 2.78
- GYRE 0.02
- Revenue
- LMB $532,913,000.00
- GYRE $100,643,000.00
- Revenue This Year
- LMB $20.01
- GYRE $21.04
- Revenue Next Year
- LMB $5.84
- GYRE $89.64
- P/E Ratio
- LMB $51.49
- GYRE $98.65
- Revenue Growth
- LMB 3.62
- GYRE N/A
- 52 Week Low
- LMB $48.17
- GYRE $6.11
- 52 Week High
- LMB $154.05
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- LMB 59.79
- GYRE 49.81
- Support Level
- LMB $139.79
- GYRE $7.49
- Resistance Level
- LMB $154.05
- GYRE $7.80
- Average True Range (ATR)
- LMB 5.60
- GYRE 0.51
- MACD
- LMB -0.28
- GYRE 0.11
- Stochastic Oscillator
- LMB 59.11
- GYRE 74.52
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.